CeriBell (NASDAQ:CBLL) Director William Burke Sells 18,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 18,000 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $26.64, for a total value of $479,520.00. Following the sale, the director directly owned 23,022 shares in the company, valued at $613,306.08. This trade represents a 43.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

CeriBell Stock Down 0.8%

CBLL stock traded down $0.21 during trading on Friday, hitting $26.14. 267,634 shares of the company’s stock were exchanged, compared to its average volume of 590,859. The business has a 50-day moving average price of $25.52 and a two-hundred day moving average price of $21.04. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.47 and a beta of 0.86. CeriBell, Inc. has a 52-week low of $12.40 and a 52-week high of $28.89.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. The company had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.18 million. As a group, equities research analysts expect that CeriBell, Inc. will post -2.05 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new position in shares of CeriBell during the second quarter worth approximately $53,000. State of Wyoming purchased a new stake in CeriBell in the 1st quarter valued at $62,000. Quantbot Technologies LP acquired a new stake in CeriBell during the 2nd quarter worth $112,000. Principal Financial Group Inc. boosted its stake in CeriBell by 71.9% during the 1st quarter. Principal Financial Group Inc. now owns 23,180 shares of the company’s stock worth $425,000 after purchasing an additional 9,696 shares during the period. Finally, Formula Growth Ltd. acquired a new stake in CeriBell during the 2nd quarter worth $603,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CBLL shares. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. TD Cowen upped their price objective on shares of CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. BTIG Research reaffirmed a “buy” rating on shares of CeriBell in a report on Wednesday, November 4th. Finally, Canaccord Genuity Group lifted their target price on CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $31.25.

CeriBell Company Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.